P&G Kisses Pharma Biz Goodbye In $3.1B Deal With Warner Chilcott
Warner Chilcott's $3.1 billion acquisition of Proctor & Gamble's pharmaceuticals business on Aug. 24 significantly bolsters the Irish drug maker's sales force and adds to its already lucrative women's health portfolio with the addition of Asacol HD and Actonel,while freeing P&G to focus on consumer health
You may also be interested in...
Three-month extension clarifies regulatory outlook for Warner Chilcott's once-weekly successor to osteoporosis blockbuster Actonel.
With the acquisition of Procter & Gamble's pharma business complete, the specialty drug maker adds 1,900 employees.
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.